REVIEW article
Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
E3 ubiquitin ligases: Structural Diversity, Dysregulation in Disease, and their emerging role in Targeted Therapeutic Strategies
Srineevas Sriram
Prahalad Krishnakumar
Sudandiradoss C
Vellore Institute of Technology, Vellore, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
The Ubiquitin-Proteasome System (UPS) is a key mechanism of cellular homeostasis. A central part of this mechanism is E3 ubiquitin ligases, which selectively direct proteins to be ubiquitinated for degradation via the UPS. In this review we give an integrated overview of the classification, structural and the functional characteristics of the main families of E3 ligases, i.e. RING, HECT, RBR and RCR E3 ligases, as well as non-canonical ligase families. Furthermore, we describe how these ligases contribute to several important biological processes like proteostasis, DNA-repair, cell-cycle control, immune-regulation and neurodegeneration. Here we present examples of diseases that occur due to abnormal functioning of E3 ligases (e.g. cancers, neurodegenerative diseases and immune dysfunctions). Finally, the review also covers emerging therapeutic strategies based on E3 ligases with an emphasis on proteolysis-targeting chimeras (PROTACs) and the use of E3 ligase-modulatory approaches to improve CAR-T-cell-based immunotherapies. Recent developments in artificial intelligence and machine learning have already transformed E3-ligase research through the possibility of high-throughput ligand screening, structure-function prediction and rational design of degraders. Our review aims to integrate our knowledge of E3 ligases and show how converging biochemistry, immunotherapy and AI-driven research can lead to novel precision strategies for targeted protein degradation.
Summary
Keywords
AI, CAR T cell, E3 ligases, PROTACs, proteostasis, Therapeutics, Ubiquitination
Received
13 November 2025
Accepted
13 February 2026
Copyright
© 2026 Sriram, Krishnakumar and C. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sudandiradoss C
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.